- radiotherapy for breast cancer
- heart-sparing radiotherapy
- stereotactic radiotherapy for oligometastatic disease
- new technologies for reducing radiotherapy toxicity
Dr Anna Kirby is a Consultant Clinical Oncologist specialising in the treatment of patients with breast cancer. She leads research into novel breast radiotherapy techniques at The Royal Marsden and Institute of Cancer Research, London. She is Chief Investigator of the UK HeartSpare studies, Chief Clinical Co-Ordinator for the IMPORT breast radiotherapy trials and breast lead investigator on the CORE trial evaluating the role of stereotactic radiotherapy in treating metastatic disease.
Dr Kirby graduated from Cambridge University in 1995 with a first-class honours degree in Medicine and Psychology. Her specialist oncology training was completed at The Royal Marsden and Guy's and St Thomas' Hospitals following which she undertook a research degree at the Institute of Cancer Research. Her publications describe methods for improving the accuracy of breast cancer radiotherapy and for reducing late side-effects of treatment including heart disease.
Her work in heart-sparing breast radiotherapy has changed national practice. Her current research interests include combining breath-hold and volumetric-modulated arc therapy to minimise heart and lung doses in women with lymph-node positive breast cancer, investigating the role of protons in breast cancer treatment, and investigating the application of MR Linac technology to partial breast irradiation,
Dr Kirby is an Examiner for the Royal College of Radiologists (RCR) and a Member of the Board of the European Society of Radiation Oncology (ESTRO).
She was made President-elect of ESTRO (Society for Radiotherapy and Oncology) in April 2020.